ABSTRACT: Patent ductus arteriosus (DA) is the second most common congenital heart defect, the incidence of which is increased in premature infants, although mechanisms responsible are not clear. Our previous studies with genetic or pharmacological inactivation of cyclooxygenase-2 (COX-2) in mice, emphasized the importance of this enzyme in normal DA closure. The current study was designed to determine whether reduced COX-2 expression contributes to patent DA in preterm mice. Real-time PCR analysis indicated that COX-2 expression in the fetal mouse DA significantly increased with advancing gestational age. Furthermore, we observed a significant induction in COX-2 expression in the DA at 3 h after birth at full-term gestation. In contrast, COX-2 expression was significantly attenuated in the DA of preterm neonatal mice. DA closure was incomplete in preterm mice at 3 h postpartum, a time-point when the DA of full-term neonates was completely remodeled. Additionally, COX-2 expression was significantly attenuated in the DA of mice deficient in the prostanoid receptor EP4, which also show a patent DA phenotype, suggesting the importance of this receptor for the induction of COX-2 required for DA closure. Overall, these studies suggest that attenuated expression of COX-2 may contribute to increased patent DA at preterm gestation. (Pediatr Res 60: 669-674, 2006) 
T he DA is a fetal artery that connects the main pulmonary artery to the descending aorta. A dilated (patent) DA in utero allows greater than 90% of the right ventricular cardiac output to bypass the high-resistance vascular beds of the uninflated lungs, and thus is vital for fetal health (1) . A failure of the DA to close after birth is a condition termed patent DA, which is the second most common congenital heart defect (2,3). Patent DA is more common in premature infants than those born at full term, however, the mechanisms responsible for the increased incidence have not been clearly established.
A number of factors such as nitric oxide, endothelin and oxygen tension have been shown to modulate ductal tone (4) . However, the agents primarily responsible for the physiologic regulation of the DA are a family of lipid mediators known as prostanoids, which include PGs and thromboxane A 2 (4) . The initial reaction in the synthesis of all prostanoids is catalyzed by two isoforms of prostanoid G/H synthase, also known as COX-1 and COX-2 (5). Individual prostanoids act through specific receptors to mediate their biologic responses.
In numerous species including humans, PGE 2 has long been known to be a potent dilator of the DA (4) . Traditionally, the predominant function of the COX isoforms expressed in the DA, was thought to be the synthesis of PGE 2 (6, 7) . We have previously reported that genetic deficiency of COX-2 results in patent DA in mice after birth, suggesting the synthesis of contractile prostanoids by COX-2, that is important in normal DA closure (8, 9) . The current study emphasizes a vital role for the induction of COX-2 in DA closure after full-term birth and suggests that attenuated COX-2 expression at preterm gestation may contribute to increased patent DA.
There are four genes that have been identified which encode the PGE 2 receptors, namely EP1, EP2, EP3, and EP4 (10) . In mice and other species, it has been known that PGE 2 mediates its dilatory actions by activating either EP2, EP3, or EP4 receptors (11) . Of the mice deficient in each of the four EP receptors, only EP4-deficient mice exhibit a patent DA phenotype, which is a paradoxical finding given the known dilatory function of this receptor (12, 13) . Our current study shows that COX-2 expression is attenuated in the DA of EP4-deficient mice, suggesting that an interplay between COX-2 and EP4 is required for initiating normal DA closure after birth.
METHODS

Animals.
The wild-type mice used in these studies (8 -10 wk of age) were on a mixed background of C57BL/6J and 129/Ola and have been maintained by continuous intercrossing with mice from the same colony, as we have reported previously (8, 9) . EP4 wild-type, heterozygous, and homozygous -deficient mice were generated by crossing EP4 heterozygous mice that were backcrossed 10 times to C57BL/6CrSlc (Japan SLC, Shizuoka, Japan). EP4 mutants were genotyped by PCR as previously described (13) . The morning after pairing was designated as gestational d 0.5 upon detection of a copulation plug. Preterm wild-type mice were delivered by cesarean section on gestational d 16 (82% gestation) or 17 (87% gestation). Full-term wild-type mice were delivered either by cesarean section or natural birth on gestational d 19.5 (100% gestation). Mice were housed under barrier conditions with food and water provided ad libitum and all experiments were conducted with the IACUC approval at the University of Kentucky.
Tissue collection and RNA isolation. Mice were euthanized in a CO 2 chamber followed by thoracotomy, to expose the heart and great vessels. Individual DAs and aortas were dissected without contamination of surrounding vessels. Tissue was individually homogenized in lysis buffer and RNA was isolated using the RNAqueous Micro Kit (Ambion, Austin, TX), which yielded ϳ150 ng total RNA per DA.
Quantitative real-time PCR analysis. Gene expression quantitation was performed in a two-step RT-PCR using Superscript II RT (Invitrogen) and Taqman chemistry. Primer/probe assays for COX-1, COX-2, EP2, EP3, EP4, and TP were purchased from Applied Biosystems (Foster City, CA). mRNA encoding the housekeeping gene, HPRT was quantitated for a normalizing control (14) . There was no significant difference in HPRT mRNA levels throughout gestation, when compared with other housekeeping genes (data not shown). Analysis was performed using the relative standard curve method. Because the expression analysis for each gene of interest was performed on separate plates, and because the primers for each gene of interest were of different efficiencies, comparison of expression levels between genes of interest was not performed. DA or aorta tissue from 1 pup was considered as an n of 1 and a minimum n of 5 was used for determining statistically significant differences (Mann-Whitney test, Kruskal-Wallis test, or two-way ANOVA).
Histology. As we have described previously (8, 9) , upper torsos were transected above the rib cage, fixed in 10% neutral buffered formalin, and processed (paraffin embedded) for histologic analysis. The entire length of the DA from the descending aorta to the bifurcation of the pulmonary arteries was serial sectioned, followed by immunohistochemical analysis for COX-2 (primary antibody from Cayman Chemical, Ann Arbor, MI) or smooth muscle actin (Dako Cytomation, Carpinteria, CA). Antibody binding was detected using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA), and sections were also stained with H and E for morphologic analysis of DA closure.
RESULTS
Attenuated constriction of the DA in preterm fetal mice.
We examined the effect of gestational age on indomethacininduced fetal DA constriction in mice. Compared with the completely patent DA of vehicle-treated controls (Fig. 1A) , indomethacin treatment induced complete occlusion of the DA of late-term fetal mice on gestational d 18.5 (Fig. 1B) . In contrast, indomethacin resulted only in partial constriction of the preterm fetal DA of mice on gestational d 16 (Fig. 1C) . These studies show that in mice, the preterm gestation fetal DA is less responsive to pharmacologically-induced constriction, and suggest that near full-term maturation is required for complete development of DA contractile function.
Expression of COX-1 and COX-2 mRNA in the fetal DA at multiple stages of gestation. We examined the time-course of COX-2 expression in the DA of fetal mice at multiple stages of gestation. To perform these studies, fetuses were obtained by cesarean section on d 16, 17, and 19.5 of gestation, and DA tissue was excised immediately (0 h) for analysis of mRNA expression. Comparative quantitative analysis of COX-2 mRNA expression showed that COX-2 expression significantly increased with advancing gestation, with the highest expression in the DA on d 19.5 ( Fig. 2A) . Furthermore, the gestation d 16 time-point with the lowest level of COX-2 mRNA coincided with the time at which we observed incomplete indomethacin-induced constriction of the fetal DA (Fig. 1C ). These data demonstrate a correlation between reduced DA constriction and attenuated COX-2 expression in the DA of preterm mice.
We also quantitated COX-1 mRNA expression in the DA at the various stages of gestation. We found that in contrast to COX-2 expression, the expression of COX-1 did not significantly change with advancing gestational age (Fig. 2B ). This finding suggests that alterations in COX-1 mRNA expression are not associated with in utero development of fetal DA contractile function.
Postnatal expression of COX-1 and COX-2 in the DA of full-term neonatal mice. We examined COX-2 mRNA expression in the DA of full-term neonates, immediately after birth (0 h) when the DA was patent, and 3 h after birth when the DA was completely closed. Quantitative real-time PCR analysis indicated that COX-2 mRNA dramatically increased (approximately 10 fold) in the DA when compared between 0 and 3 h postpartum on gestational d 19.5 (Fig. 3A) . This increase in COX-2 mRNA expression from 0 to 3 h after birth was unique to the DA, as no such increase in COX-2 expression was observed in the adjacent aorta. We also examined COX-2 protein expression by immunohistochemistry and found that significant COX-2 protein was localized in the smooth muscle cells of the DA with evidence of perinuclear expression, but not in the smooth muscle cells of the adjacent aorta (Fig. 3 B) . Therefore, a significant increase in smooth muscle cell expression of COX-2 accompanies closure of the DA after full-term birth. 
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We also compared COX-1 expression in the full-term neonatal mouse DA between 0 and 3 h of birth. In contrast to COX-2 expression, the expression of COX-1 mRNA was constitutive with no significant difference between the two time-points (Fig. 3C) .
Incomplete postnatal closure of the DA in preterm neonatal mice. The effect of prematurity on DA closure was determined by comparing the DAs of neonates delivered at preterm gestation with those delivered at full-term gestation. Our findings indicate that DA closure was complete in all neonates analyzed at 3 h after full-term birth on d 19.5 (Fig.  4A) . In contrast, significant lumen was visible in the DAs of all preterm neonates that were analyzed at 3 h postpartum on gestational d 17 (Fig. 4B) . These findings indicate that the DAs of neonatal mice born premature show incomplete closure.
Postnatal expression of COX-1 and COX-2 in the DA of preterm neonatal mice. To determine whether the incomplete closure of the DA in preterm neonatal mice that we observed (Fig. 4) was associated with attenuated expression of COX-2, we compared COX-2 expression in the DAs between preterm (d 17) and full-term (d 19.5) neonates at 3 h after birth. In comparison to the level of expression observed in the DA of full-term neonates, COX-2 mRNA expression in the DA of preterm neonates, was significantly lower (Fig. 5A) . The attenuated COX-2 expression coincided with the time-point at which we observed incomplete closure of the DA at preterm (Fig. 4B) . In contrast to COX-2 expression, there was no significant difference in COX-1 mRNA expression between DAs from preterm and full-term neonatal mice at 3 h postpartum (Fig. 5B) . Immunohistochemical analysis of COX-2 protein expression indicated that the DA of full-term neonatal mice showed significantly greater number of COX-2-positive cells than the DA of preterm neonatal mice (Fig. 5,  C and D) . Furthermore, the COX-2 expression was primarily localized in the smooth muscle cells of the DA (Fig. 5E) . Thus, these data establish a direct correlation between the attenuated COX-2 expression and increased patent DA.
Quantitation of prostanoid receptors in the fetal DA at multiple stages of gestation. Previous reports have suggested that the prostanoid receptors EP2, EP3, EP4, and TP may be involved in modulating DA tone (9, 11, 15, 16) . In the current studies, we examined mRNA expression levels for these prostanoid receptors. As shown in Figure 6A , the fetal mouse DA expressed a significant level of TP, however, the level of expression did not significantly change throughout gestation. EP2 mRNA expression was nearly undetectable in the fetal DA (data not shown). The expression of EP3 mRNA was constitutive in the fetal DA, when examined on d 16, 17, and 19.5 of gestation (Fig. 6B) . In contrast, expression of the EP4 receptor in the fetal mouse DA increased significantly from gestational d 16 to 19.5 (Fig. 6C) .
Reduced COX-2 mRNA expression in the DA of EP4-deficient neonatal mice. In addition to the COX-deficient mice, mice deficient in the PGE 2 receptor EP4 also exhibit a patent DA phenotype (12, 13) . This finding is surprising because it is well established that PGE 2 produces dilation of the DA (4). Furthermore, there is no evidence that EP4 receptor activation directly induces constriction of the smooth muscle of the DA or any other vasculature. We hypothesized that the expression of EP4 may be required for the induction of COX-2, important for normal DA closure. We therefore compared COX-2 expression in the DA of EP4-deficient and EP4-expressing neonatal mice. Our results indicate that COX-2 expression is significantly attenuated in the DAs of EP4-deficient mice at 3 h after birth, compared with the DAs of littermate EP4 heterozygous or wild-type mice (Fig. 7) .
DISCUSSION
In humans, patent DA is more common in premature infants, than those born at full-term, although mechanisms responsible for the increased incidence are poorly understood. We have previously reported that genetic or pharmacological inactivation of COX-2 results in patent DA in mice, indicating the importance of COX-2 in postnatal closure of the DA (8, 9) . The current studies were aimed at better understanding the COX-2-dependent mechanisms of DA closure and elucidating the factors responsible for patent DA at preterm gestation. Our findings are the first to suggest that reduced expression of COX-2 in the DA at preterm gestation contributes to increased patent DA.
Fetal DA constriction induced by the nonselective COX inhibitor indomethacin has long been used to study pharmacologically induced contractile responses in the DA (17) . Maternal administration of indomethacin results in premature constriction of the DA by inhibiting the synthesis of prostanoids important for DA dilation (4). We have reported that similar to previous studies with indomethacin, acute administration of COX-2-selective inhibitors results in premature DA constriction, whereas chronic administration of COX-2 inhibitors results in postnatal patent DA in mice (9) . A more recent report replicated these studies and showed similar results (18) . These contrasting effects suggest opposing actions of different prostanoids on the regulation of DA tone. However, mechanisms by which acute indomethacin administration results in DA constriction in utero, without affecting postnatal DA closure, remain to be fully elucidated. Nevertheless, acute maternal administration of indomethacin is an effective functional marker for fetal DA constriction.
Previous studies in rats and humans have shown that the preterm fetal DA is less responsive to indomethacin-induced constriction, in contrast to the DA of full-term fetuses (19, 20) . In the current studies, we examined the effect of gestational age on indomethacin-induced fetal DA constriction in mice. Our results show that the preterm fetal DA on gestational d 16 is less responsive to the constricting effects of indomethacin, compared with the late gestation fetal DA on d 18.5. Therefore, in mice the contractile nature of the DA develops late in gestation.
We have previously reported that the DA of COX-2-deficient fetuses fails to constrict in response to indomethacin, suggesting the importance of COX-2 expression for in utero contractile function (8) . Therefore, in the current study, we investigated the relationship between the ontogeny of COX-2 expression and the developmental regulation of fetal DA constriction. COX-2 expression in the DA was significantly greater in full-term fetuses than that in preterm fetuses. Our previous report, together with our current study suggest that the contractile function of the DA that develops toward the end of term requires the in utero increase in COX-2 expression with advancing gestational age.
Normal DA closure in mice at full-term gestation is complete within 3 h after birth. With our finding that incomplete development resulted in attenuated fetal DA constriction, we investigated whether prematurity in gestation also compromised normal DA closure after birth. We observed that at 3 h postpartum, DA closure was incomplete in preterm neonates, in contrast to the completely remodeled DA of 3 h-old neonates born at full-term gestation. This suggests that similar to humans, premature birth compromises postnatal DA closure in mice.
The factors responsible for inducing normal closure of the DA after birth have not been clearly defined. Our previous studies using mice deficient in COX-2, clearly demonstrate the importance of this enzyme in postnatal DA closure (8) . In mice, DA closure commences within 30 min after full-term birth. Our current studies show that COX-2 expression is dramatically induced in the neonatal DA within 3 h of birth at full-term gestation, which correlates with the time-point when the DA is completely remodeled. This suggests that induction of COX-2 expression in the DA may be required for achieving permanent closure after full-term birth. Therefore, we hypothesized that the incomplete closure of the DA in preterm gestation neonatal mice that we observed, may result from attenuated expression of COX-2. In support of this hypothesis, we found that COX-2 expression was significantly lower in the DAs of neonatal mice delivered at preterm gestation, compared with that expressed in the DAs of full-term neonates. The reduced COX-2 expression corresponded with the time-point at which we observed incomplete closure of the preterm neonatal DA. Thus, our studies demonstrate a direct correlation between the attenuated expression of COX-2 and the failure of complete closure of the DA at preterm gestation.
Previous studies examining developmental regulation of the COX isoforms in the DA have focused on the action of these enzymes in DA dilation. In other species, it has been reported that COX-1 is the predominant isoform expressed in the premature fetal DA, whereas COX-2 is primarily expressed in the DA late in gestation (6, 21) . Our current findings in mice are in agreement with previous reports, and show that COX-1 is constitutively expressed in the DA throughout gestation, and COX-2 is induced in the DA from preterm to full-term gestation. It has also been suggested that the DA at preterm gestation is more sensitive to dilation in response to PGE 2 derived from the activity of COX-1, a process that may contribute to increased postnatal patent DA (6, 11) . Our work emphasizes the importance of COX-2 in mediating DA closure. Because of its potent dilatory effect, it is unlikely that PGE 2 is the COX-2-derived prostanoid that induces DA closure. We propose that COX-2 expressed in the DA synthesizes a prostanoid other than PGE 2 , which directly mediates DA closure. Therefore, patent DA at preterm gestation may result from constitutive expression of COX-1 together with the attenuated expression of COX-2.
Because PGE 2 is a known potent dilator of the DA, several studies in numerous species have focused on examining EP receptor expression in the DA to better understand the role of PGE 2 in modulating DA tone. Depending on the species, gene expression in the DA for EP2, EP3, and EP4 does not change, decreases, or increases with advancing gestation (11, 15, 16) . Of the EP receptors that we examined in our current studies, only EP4 mRNA expression significantly increased with advancing gestation. Furthermore, the gestational expression pattern of EP4 mimicked that which we observed for COX-2. The co-regulation of EP4 and COX-2 suggests a relationship between this prostanoid receptor and COX-2, for inducing DA closure.
In addition to the COX-2-deficient mice, mice deficient in the EP4 receptor also exhibit a patent DA phenotype (12, 13) . This finding is surprising because it is well established that PGE 2 produces dilation of the DA. The proposed mechanism for patent DA in the EP4-deficient mice was that the loss of EP4 results in persistent levels of cAMP, which maintain DA dilation (12) . A recent report has shown that cAMP levels are increased in the premature ovine DA, making the DA more sensitive to dilation (11) . Based on these previous reports, it is possible that the patent DA we observe at preterm gestation in mice, may be due to reduced levels of EP4 and resultant increased levels of cAMP, in addition to attenuated expression of COX-2.
EP4 activation is known to induce COX-2 expression in multiple cell types (22, 23) . Our studies indicate that the genetic deficiency of EP4 results in attenuated COX-2 expression in the DA and COX-2 is important for DA closure. Thus, our results provide an explanation for the paradoxical finding of patent DA in the EP4-deficient mice, and suggest that EP4 expression may be important for modulating the normal in-673 COX-2 AND DUCTUS ARTERIOSUS CLOSURE duction of COX-2 and resultant DA closure after full-term birth.
